|
|
|
|
 Prof Rolf Bjerkvig,
Scientific Director Norlux-Neuro Oncology Dr. Bjerkvig is Professor in Cell Biology at the University of Bergen, Norway and is co-directing the NorLux Neuro-Oncology laboratories located in Luxembourg and Norway (www.norlux.lu). Bjerkvig
has acted as a vice chairman, and chairman of the Department of Anatomy and Cell Biology as well as chairman of the department of Biomedicine, University of Bergen, Norway. He has also acted a co-director of the National Gene Therapy Programme in Norway. At present he is coordinating the Integrated project Angiotargeting within the 6th framework programme of the European Commission involving 13 European Research Institutions (www.uib.no/med/angiotargeting).
Bjerkvig has served in numerous national and international committees related to cancer research, which includes evaluation committees for the Norwegian Research Council, the Norwegian Cancer Society, the Swedish Research Council, Swedish and Finnish centers of excellence, the Luxembourg Forsight programme, Max-Plank Society as well as the European Commission (5th and 6th Framework Programme).
Bjerkvig received his basic academic training at the Brain Tumor Research Center, University of California San Francisco. He has worked as a research scientist at the Norwegian Cancer Society affiliated to the Gade Institute, Department of Pathology, at Haukeland Hospital, Bergen. His main interests are to elucidate the mechanisms that cause tumour cell migration within the CNS. In later years his research has focused on mechanisms of cancer initiation and progression with particular emphasis on cancer initiating cells. His research is also focused on mechanisms of tumor angioegenesis and therapeutic approaches that will prevent angiogenesis in brain tumors.
He receives major grants from the Norwegian Research Council, The Norwegian Cancer Society, The National Gene Therapy Programme of Norway, Fonds National Recherche, Luxembourg and the European Commission. He is on the editorial board on several international journals and is sitting in several national as well as international funding committees for cancer in Europe. He has published more than 144 articles (indexed in Pub med), and been an invited lecturer to 218 international
conferences.
Appearing: DAY 2 WEDNESDAY 22 SEPTEMBER – IMPROVING PRE-CLINICAL & EARLY DEVELOPMENT 5.40pm Case study: optimising pre-clinical animal models of glioblastoma multiforme for target identification
- Practical considerations for establishing better pre-clinical models for GBD.
- Evaluating the relevance of pre-clinical models to the early-stages of tumour growth in humans.
- Applying proteomics to pre-clinical models for the validation of new targets.
Prof Rolf Bjerkvig, Scientific Director,
Norlux-Neuro Oncology |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
